Across TCGA pan-cancer cohorts, MARCHF11 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated MARCHF11 data layer compared with 5 for mutation status.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MARCHF11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MARCHF11 expression acts as an unfavorable survival marker, although some lineages such as LGG and BRCA show a favorable association.
DLBC, COAD, and UCEC are the cancer types where MARCHF11 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.